8-K: Onconetix Issues New Investment Options Following Warrant Exercise, Expects $1.11 Million in Gross Proceeds

Onconetix, Inc. has entered into agreements for the exercise of existing warrants, resulting in new investment options and expected gross proceeds of approximately $1.11 million.

Summary

• Onconetix, Inc. has agreed with certain holders of existing preferred investment options (PIOs) to exercise their options for cash.
• The existing PIOs, originally issued in August 2022 and August 2023 with exercise prices of $2.546 and $1.09 per share respectively, will be exercised at a reduced price of $0.15 per share.
• In exchange for exercising these existing PIOs, the holders will receive new preferred investment options (Inducement PIOs) to purchase up to 22,375,926 shares of common stock.
• The company expects to receive approximately $1,118,796 in gross proceeds from the exercise of the existing PIOs and the sale of the new Inducement PIOs.
• The net proceeds will be used for general corporate and working capital purposes.
• The closing of the transaction is expected to occur on July 12, 2024, subject to customary closing conditions.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction and will receive a cash fee of 7.5% of the gross proceeds, a management fee of 1.0% of the gross proceeds, and reimbursement for expenses up to $85,000.
• The company will also issue warrants to the placement agent to purchase 522,105 shares at $0.1875 per share and additional warrants based on the exercise of the Inducement PIOs.
• The new Inducement PIOs will have an exercise price of $0.15 per share.
• One-third of the new warrants will have a term of exercise of five years, and the remaining two-thirds will have a term of exercise of twenty-four months, both starting from the date of stockholder approval.
• The issuance of shares upon exercise of the new warrants is subject to stockholder approval, which the company will seek at a meeting within 90 days of the closing date.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company as it secures funding through warrant exercises. However, the need for stockholder approval and the restrictions on future issuances introduce some uncertainty.

Positives

• The company is expected to receive $1.11 million in gross proceeds, which will be used for working capital and general corporate purposes.
• The exercise of existing warrants at a reduced price may encourage further investment.
• The new preferred investment options provide an opportunity for future capital raising.
• The company has engaged a placement agent to assist with the transaction.
• The resale of shares from the existing warrants is already registered, and the company will register the resale of shares from the new warrants.

Negatives

• The new warrants are unregistered and subject to resale restrictions.
• The issuance of shares upon exercise of the new warrants is subject to stockholder approval, which introduces uncertainty.
• The company is paying significant fees to the placement agent, including cash fees, expense reimbursements, and warrants.
• The company has agreed to restrictions on issuing new shares or filing new registration statements for a period of time.
• The company has agreed to restrictions on variable rate transactions for six months.

Risks

• The transaction is subject to customary closing conditions, which may not be met.
• The company may not receive the full $1.11 million in gross proceeds due to placement agent fees and other expenses.
• The company may not obtain stockholder approval for the issuance of shares upon exercise of the new warrants.
• The new warrants are not listed on any exchange, which may limit their liquidity.
• The company is subject to restrictions on issuing new shares or filing new registration statements for a period of time.
• The company is subject to restrictions on variable rate transactions for six months.
• The company's ability to commercialize its products is subject to various risks, including regulatory approvals and market acceptance.

Future Outlook

The company expects to use the net proceeds from the transaction for working capital and general corporate purposes. The company will seek stockholder approval for the issuance of shares upon exercise of the new warrants. The company will file a resale registration statement for the shares issuable upon exercise of the new warrants within 30 days.

Management Comments

• Onconetix is pleased to offer the opportunity to receive new preferred investment options and a reduction in the exercise price of existing options.
• The company expects to use the net proceeds from the transaction for working capital and general corporate purposes.

Industry Context

This announcement reflects a common strategy for companies to raise capital by incentivizing the exercise of existing warrants and issuing new investment options. This is particularly relevant for biotechnology companies that require capital for research, development, and commercialization activities.

Comparison to Industry Standards

• The use of a placement agent and the payment of fees and warrants is standard practice in capital raising transactions.
• The terms of the new warrants, including the exercise price and term, are within the typical range for such instruments.
• The requirement for stockholder approval for the issuance of shares is a common practice to ensure shareholder oversight.
• The restrictions on issuing new shares and variable rate transactions are also common in such agreements to protect the interests of the investors.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of new shares upon exercise of the warrants.
• Employees may benefit from the increased working capital and the company's ability to execute its business plan.
• Customers may benefit from the company's ability to invest in its products and services.
• Creditors may benefit from the company's improved financial position.

Next Steps

• The company will close the transaction on or about July 12, 2024.
• The company will convene a stockholders meeting within 90 days to obtain approval for the issuance of shares upon exercise of the new warrants.
• The company will file a resale registration statement for the shares issuable upon exercise of the new warrants within 30 days.

Key Dates

Keywords

preferred investment options, warrants, common stock, exercise price, placement agent, stockholder approval, registration statement, capital raise, private placement, working capital